Chao Zheng1, Liang He2, Lingling Liu1, Jie Zhu3, Tao Jin4. 1. Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Xinmin Street 71, Changchun 130021, China. 2. Department of Urinary Surgery, The First Hospital of Jilin University, Changchun, China. 3. Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Xinmin Street 71, Changchun 130021, China; Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden. 4. Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Xinmin Street 71, Changchun 130021, China. Electronic address: drtao.jin@hotmail.com.
Abstract
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder in the central nervous system (CNS) leading to a high level of neurological disability. The pathogenesis of MS remains largely unknown, which explains the lack of significant efficacy of therapy in MS. Vitamin D deficiency is widely considered to be an environmental risk factor for MS. Many studies investigating the therapeutic effects of vitamin D on MS have been applied. The objective of this systematic review and meta-analysis was to evaluate the effectiveness of vitamin D in MS patients. METHODS: To obtain a more comprehensive estimate of the efficacy of vitamin D on MS patients, we conducted a meta-analysis to determine the role of vitamin D in MS. The PubMed, EMBASE and Cochrane databases were searched in October 2017. Randomized, double-blind, placebo-controlled clinical trials recorded within the three main databases were considered. The analysis was conducted for two specific outcomes: Expanded Disability Status Scale (EDSS) score and annual relapse rate (ARR). RESULTS: Vitamin D3 as add-on treatment had no significant therapeutic effect on MS according to EDSS score (mean difference -0.01 [95% CI -0.34 to 0.33]). The ARR was higher in the vitamin D group than in the placebo group (mean difference 0.05 [95% CI 0.01 to 0.1]). CONCLUSION: Our findings suggest that vitamin D appeared to have no therapeutic effect on EDSS score or ARR in the patients with MS.
BACKGROUND:Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder in the central nervous system (CNS) leading to a high level of neurological disability. The pathogenesis of MS remains largely unknown, which explains the lack of significant efficacy of therapy in MS. Vitamin D deficiency is widely considered to be an environmental risk factor for MS. Many studies investigating the therapeutic effects of vitamin D on MS have been applied. The objective of this systematic review and meta-analysis was to evaluate the effectiveness of vitamin D in MS patients. METHODS: To obtain a more comprehensive estimate of the efficacy of vitamin D on MS patients, we conducted a meta-analysis to determine the role of vitamin D in MS. The PubMed, EMBASE and Cochrane databases were searched in October 2017. Randomized, double-blind, placebo-controlled clinical trials recorded within the three main databases were considered. The analysis was conducted for two specific outcomes: Expanded Disability Status Scale (EDSS) score and annual relapse rate (ARR). RESULTS:Vitamin D3 as add-on treatment had no significant therapeutic effect on MS according to EDSS score (mean difference -0.01 [95% CI -0.34 to 0.33]). The ARR was higher in the vitamin D group than in the placebo group (mean difference 0.05 [95% CI 0.01 to 0.1]). CONCLUSION: Our findings suggest that vitamin D appeared to have no therapeutic effect on EDSS score or ARR in the patients with MS.
Authors: Lawrence T C Ong; Grant P Parnell; Kelly Veale; Graeme J Stewart; Christopher Liddle; David R Booth Journal: Genes Immun Date: 2020-10-09 Impact factor: 2.676
Authors: Emmanuelle Waubant; Robyn Lucas; Ellen Mowry; Jennifer Graves; Tomas Olsson; Lars Alfredsson; Annette Langer-Gould Journal: Ann Clin Transl Neurol Date: 2019-08-07 Impact factor: 4.511
Authors: Vanitha A Jagannath; Graziella Filippini; Carlo Di Pietrantonj; G V Asokan; Edward W Robak; Liz Whamond; Sarah A Robinson Journal: Cochrane Database Syst Rev Date: 2018-09-24
Authors: Friederike Maretzke; Angela Bechthold; Sarah Egert; Jana B Ernst; Debora Melo van Lent; Stefan Pilz; Jörg Reichrath; Gabriele I Stangl; Peter Stehle; Dorothee Volkert; Michael Wagner; Julia Waizenegger; Armin Zittermann; Jakob Linseisen Journal: Nutrients Date: 2020-03-31 Impact factor: 5.717